192 related articles for article (PubMed ID: 23087187)
1. Bone marrow-induced Mef2c deficiency delays B-cell development and alters the expression of key B-cell regulatory proteins.
Debnath I; Roundy KM; Pioli PD; Weis JJ; Weis JH
Int Immunol; 2013 Feb; 25(2):99-115. PubMed ID: 23087187
[TBL] [Abstract][Full Text] [Related]
2. MEF2C and EBF1 Co-regulate B Cell-Specific Transcription.
Kong NR; Davis M; Chai L; Winoto A; Tjian R
PLoS Genet; 2016 Feb; 12(2):e1005845. PubMed ID: 26900922
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-β1 regulates expression of the matrix metalloproteinase 20 (Mmp20) gene through a mechanism involving the transcription factor, myocyte enhancer factor-2C, in ameloblast lineage cells.
Gao Y; Zhang L; Xiang L; Li B; Liu X; Wang Y; Sun Y
Eur J Oral Sci; 2014 Apr; 122(2):114-20. PubMed ID: 24495128
[TBL] [Abstract][Full Text] [Related]
4. Identification of the Regulatory Elements and Target Genes of Megakaryopoietic Transcription Factor MEF2C.
Kong X; Ma L; Chen E; Shaw CA; Edelstein LC
Thromb Haemost; 2019 May; 119(5):716-725. PubMed ID: 30731491
[TBL] [Abstract][Full Text] [Related]
5. Essential control of early B-cell development by Mef2 transcription factors.
Herglotz J; Unrau L; Hauschildt F; Fischer M; Kriebitzsch N; Alawi M; Indenbirken D; Spohn M; Müller U; Ziegler M; Schuh W; Jäck HM; Stocking C
Blood; 2016 Feb; 127(5):572-81. PubMed ID: 26660426
[TBL] [Abstract][Full Text] [Related]
6. Mef2c regulates bone mass through Sost-dependent and -independent mechanisms.
Morfin C; Sebastian A; Wilson SP; Amiri B; Murugesh DK; Hum NR; Christiansen BA; Loots GG
Bone; 2024 Feb; 179():116976. PubMed ID: 38042445
[TBL] [Abstract][Full Text] [Related]
7. MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice.
Mitchell AC; Javidfar B; Pothula V; Ibi D; Shen EY; Peter CJ; Bicks LK; Fehr T; Jiang Y; Brennand KJ; Neve RL; Gonzalez-Maeso J; Akbarian S
Mol Psychiatry; 2018 Jan; 23(1):123-132. PubMed ID: 28115742
[TBL] [Abstract][Full Text] [Related]
8. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes.
Swanson BJ; Jäck HM; Lyons GE
Mol Immunol; 1998 Jun; 35(8):445-58. PubMed ID: 9798649
[TBL] [Abstract][Full Text] [Related]
9. Function analysis of Mef2c promoter in muscle differentiation.
Jin W; Liu M; Peng J; Jiang S
Biotechnol Appl Biochem; 2017 Sep; 64(5):647-656. PubMed ID: 27354201
[TBL] [Abstract][Full Text] [Related]
10. Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter.
Rao S; Karray S; Gackstetter ER; Koshland ME
J Biol Chem; 1998 Oct; 273(40):26123-9. PubMed ID: 9748293
[TBL] [Abstract][Full Text] [Related]
11. CAIII expression in skeletal muscle is regulated by Ca
Huang H; Zhao Y; Shang X; Ren H; Zhao Y; Liu X
Exp Cell Res; 2019 Dec; 385(1):111672. PubMed ID: 31614133
[TBL] [Abstract][Full Text] [Related]
12. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis.
Gekas C; Rhodes KE; Gereige LM; Helgadottir H; Ferrari R; Kurdistani SK; Montecino-Rodriguez E; Bassel-Duby R; Olson E; Krivtsov AV; Armstrong S; Orkin SH; Pellegrini M; Mikkola HK
Blood; 2009 Apr; 113(15):3461-71. PubMed ID: 19211936
[TBL] [Abstract][Full Text] [Related]
13. MEF2C regulates NK cell effector functions through control of lipid metabolism.
Li JH; Zhou A; Lee CD; Shah SN; Ji JH; Senthilkumar V; Padilla ET; Ball AB; Feng Q; Bustillos CG; Riggan L; Greige A; Divakaruni AS; Annese F; Cooley Coleman JA; Skinner SA; Cowan CW; O'Sullivan TE
Nat Immunol; 2024 May; 25(5):778-789. PubMed ID: 38589619
[TBL] [Abstract][Full Text] [Related]
14. Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival.
Chen HC; Byrd JC; Muthusamy N
J Immunol; 2006 Feb; 176(4):2208-18. PubMed ID: 16455977
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular development and survival require Mef2c function in the myocardial but not the endothelial lineage.
Materna SC; Sinha T; Barnes RM; Lammerts van Bueren K; Black BL
Dev Biol; 2019 Jan; 445(2):170-177. PubMed ID: 30521808
[TBL] [Abstract][Full Text] [Related]
16. The B lymphocyte-specific coactivator BOB.1/OBF.1 is required at multiple stages of B-cell development.
Hess J; Nielsen PJ; Fischer KD; Bujard H; Wirth T
Mol Cell Biol; 2001 Mar; 21(5):1531-9. PubMed ID: 11238890
[TBL] [Abstract][Full Text] [Related]
17. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
[TBL] [Abstract][Full Text] [Related]
18. Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells.
Andrews SF; Dai X; Ryu BY; Gulick T; Ramachandran B; Rawlings DJ
Eur J Immunol; 2012 May; 42(5):1327-36. PubMed ID: 22311635
[TBL] [Abstract][Full Text] [Related]
19. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine phenotypes in a boy with 5q14 deletion syndrome implicate the regulatory roles of myocyte-specific enhancer factor 2C in the postnatal hypothalamus.
Sakai Y; Ohkubo K; Matsushita Y; Akamine S; Ishizaki Y; Torisu H; Ihara K; Sanefuji M; Kim MS; Lee KU; Shaw CA; Lim J; Nakabeppu Y; Hara T
Eur J Med Genet; 2013 Sep; 56(9):475-83. PubMed ID: 23832106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
